Edward M. Messing, M.D.

I chose this field because half of all cancers in men – and almost 20% in women – arise in urologic organs and are treated by urologists. Specializing in urologic oncology is a way of helping many people.

Since I believe that an informed patient makes the wisest decisions regarding treatment, I spend much time educating my patients about their disease and options for treatment. My approach to patient care is individualized, both in terms of treatments offered and recommended, and in terms of the patient's and his or her family's goals. Treating bladder, kidney, prostate and testicular cancer are among my areas of expertise. I also hold several research grants and patents related to the field of urologic cancer.

Conditions I Treat:

- Bladder cancer
- Kidney cancer
- Prostate cancer
- Testicular cancer
- Adrenal cancer
- Penile cancer
- Scrotal cancer
- Ureteral cancer
- Urethral cancer

Professional Background

Dr. Messing received his MD degree from New York University in 1972, had his surgery training at NYU-Bellevue Hospital in New York 1972-1974, and his Urology Residency at Stanford University 1974-1978. After 2 years on the faculty at Tulane University, he completed a fellowship in Urologic Oncology at UCLA in 1982. He was on the faculty of the Division of Urology at the University of Wisconsin from 1982-1995, being Director of their Urologic Oncology Program for the last 10 years. He became The W.W. Scott Professor and Chairman of the Department of Urology and maintained that position until he stepped down as Chairman in January, 2018. He remains an active clinician and surgeon and is a Professor of Urology, Oncology, and Pathology at University of Rochester. At the University of Rochester School of Medicine and Dentistry(UR) in September 1995, Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the prostate, bladder, kidney, testicle, penis and other genitourinary organs, carries on extensive research in the basic biology of bladder and prostate cancers, and has been the principal investigator on numerous clinical studies for the detection, prevention and treatment of genitourinary cancers.

Dr. Messing has held numerous leadership positions in institutional, local , regional and national organizations including being a department chairman or over 22 years. interim director of the National Cancer Institute, URMC Cancer Center, being a board member, officer and president of both The Society of Urological Oncology and The North Western Section of the American Urological Association (NSAUA), co chairman of the Genitourinary Group (GU) of the Eastern Cooperative Oncology Group (ECOG) and co-leader of the Renal Cancer Subcommittee of the GU committee of SWOG. (The South West Oncology Group) In September, 2021 he will become the President-elect of the American Urological Association (AUA) to become President May, 2022.

Research